TNF inhibitors and structural damage in ankylosing spondylitis-Reference-Cited by-同舟云学术

TNF inhibitors and structural damage in ankylosing spondylitis

Published:2017-12-07 Issue:1 Volume:14 Page:5-6
ISSN:1759-4790
Container-title:Nature Reviews Rheumatology
language:en
Short-container-title:Nat Rev Rheumatol

Author:

Deodhar Atul

Publisher

Springer Science and Business Media LLC

Subject

Rheumatology

Link

http://www.nature.com/articles/nrrheum.2017.197.pdf

Reference10 articles.

1. Molnar, C. et al. TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann. Rheum. Dis. http://dx.doi.org/10.1136/annrheumdis-2017-211544 (2017).

2. van der Heijde, D. et al. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum. 58, 1324–1331 (2008).

3. van der Heijde, D. et al. Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum. 58, 3063–3070 (2008).

4. van der Heijde, D. et al. Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res. Ther. 11, R127 (2009).

5. Haroon, N. et al. The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum. 65, 2645–2654 (2013).

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CD_99 G1 neutrophils modulate osteogenic differentiation of mesenchymal stem cells in the pathological process of ankylosing spondylitis;Annals of the Rheumatic Diseases;2023-11-17

2. Elevated BMPR2 expression amplifies osteoblast differentiation in ankylosing spondylitis;Journal of Rheumatic Diseases;2023-07-28

3. APPLICATIONS OF THE EXTENSION INNOVATION METHOD IN TREATMENT REGIMENS GENERATION WITH DEEP LEARNING;Journal of Mechanics in Medicine and Biology;2023-01-28

4. Rebuttal letter on “Comment on Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis—time to reconsider treatment guidelines? A case series and review of literature”;Clinical Rheumatology;2021-03-22

5. Aberrant upregulation of CaSR promotes pathological new bone formation in ankylosing spondylitis;EMBO Molecular Medicine;2020-12